Preventive therapy of breast cancer: an update

WEB CONFERENCE

9.00 Welcome address Andrea De Censi – Bernardo Bonanni

I Session
Risk Stratification
Chair: Bernardo Bonanni
9.10    High-Risk mutation carriers: opportunities and challenges for non surgical prevention – Laura Cortesi
9.30    Breast Intraepitelial Neoplasia – Mariangela Rutigliani
9.50    Biomarkers of risk in DCIS – Matteo Lazzeroni
10.10 Mammography density  and polygenic risk score as surrogate biomarker for prevention – Jack Cuzick

II Session
Baby Tamoxifen and baby Exemestane: where do we stand?
Chair: Andrea De Censi
10.30 Drug metabolites during Baby Tamoxifen. Is there a magic threshold?  – Gunnar Mellgren
10.50 Comparison between physician and patient experience in the Baby Tamoxifen Trial-Tania Buttiron Webber
11.10  The window of opportunity trial model focusing on a randomized phase II Trial “Baby Exemestane” – Aliana Guerrieri Gonzaga, Davide Serrano
11.30 What’s next? Comparing baby Tamoxifen with AIs – Jose Enrique Ales Martinez
11.50 Magistral Lecture: Breast Cancer prevention, a lot to do yet – Jack Cuzick

12.30 Lunch Break

III Session
New Drugs for the treatment of advanced disease with preventive potential
Chair: Giuseppe Curigliano
14.00 PARP inhibitors for breast and ovarian cancer –  Paolo Pronzato
14.20 CDK4-6 inhibitors – Giuseppe Curigliano
14.40 Denosumab for bone health and breast cancer prevention – Nicoletta Provinciali

IV Session
New prevention ideas for trials: opportunities and challenges
Chair: Andrea De Censi
15.00 A review of the NCI sponsored Trials- Brandy Heckman-Stoddard
15.20 Topical  4OH Tamoxifen gel metabolites – Banu Arun
15.40 Intermittent fasting and Metformin – Irene M. Briata
16.00 Low dose Tamoxifen in irradiated women – Smita Bhatia

16.20 Round Table: The future of breast cancer prevention
Jose Enrique Ales Martinez, Banu Arun, Bernardo Bonanni, Karen Brown, Powel Brown, Jack Cuzick, Laura Cortesi, Andrea De Censi, Brandy Heckman-Stoddard

17.30 Adjournment
Andrea De Censi
Bernardo Bonanni